Biomea Fusion's experimental drug showed sustained blood sugar control in patients with type 2 diabetes and may benefit those not responding to GLP-1 therapies like Novo Nordisk's Ozempic, it said on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback